FOI Request
- Disclosure ID
- FOI/02519
- Request Date
- June 21, 2018
- Subject
- Biological And Biosimilar Medicines (Advanced Therapy)
- Description
Within your Trust and over the last three months, how many Psoriasis [PsO] patients have been initiated on their first advanced therapy (i.e. Biologic, Apremilast or Dimethyl fumarate)? Total New Advanced Therapy patient Initiations. Where possible please split by treatment;
- Response
Adalimumab [Humira] 103 Apremilast [Otezla] 14 Brodalumab [Kyntheum] 0 Certolizumab [Cimzia] 1 Dimethyl fumarate [Skilarence] 0 Etanercept [Enbrel] 9 Etanercept Biosimilar 1 Guselkumab [Tremfya] 0 Infliximab [Remicade] 6 Infliximab Biosimilar 0 Ixekizumab [Taltz] 2 Secukinumab [Cosentyx] 18 Ustekinumab [Stelara] 92